Compare ESQ & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | EVO |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 1.1B |
| IPO Year | 2017 | N/A |
| Metric | ESQ | EVO |
|---|---|---|
| Price | $109.72 | $3.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $120.33 | $7.00 |
| AVG Volume (30 Days) | ★ 77.0K | 47.1K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.15 | $1.37 |
| Revenue Next Year | $39.09 | $10.05 |
| P/E Ratio | $78.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.54 | $2.31 |
| 52 Week High | $119.86 | $4.42 |
| Indicator | ESQ | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 56.03 |
| Support Level | $103.31 | $2.88 |
| Resistance Level | $111.41 | $3.75 |
| Average True Range (ATR) | 2.81 | 0.07 |
| MACD | 0.36 | 0.01 |
| Stochastic Oscillator | 58.02 | 89.58 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.